Strategy in the treatment of anthracycline-resistant breast cancer
Xu, B.-h.
Zhonghua Zhong Liu Za Zhi 29(4): 241-244
2007
ISSN/ISBN: 0253-3766 PMID: 17760246 Document Number: 606837
Document emailed within 1 workday
Related Documents
Oura, S.; Sakurai, T.; Yoshimura, G.; Tamaki, T.; Umemura, T.; Kokawa, Y.; Naito, Y.; Suzuma, T.; Tanino, H. 1999: Docetaxel therapy against anthracycline resistant breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(6): 781-788Kubo, H.; Kijima, D.; Tada, K.; Miyahara, M.; Hasegawa, H. 2010: A case of anthracycline- and taxane-resistant recurrent advanced breast cancer successfully treated with S-1 monotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(7): 1325-1327
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
Belohorska, B.; Svec, J.; Vertakova-Krakovska, B.; Tkacova, M. 2009: Treatment strategy of the HER 2 positive breast cancer with CNS metastases Bratislavske Lekarske Listy 110(5): 324
Yoshizawa, K. 2002: Latest treatment strategy for pulmonary metastases in breast cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 5): 521-525
Kitagawa, D.; Toi, M. 2007: Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 65 Suppl. 6: 396-401
Faneyte, I.F.; Kristel, P.M.P.; van de Vijver, M.J. 2004: Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer Anticancer Research 24(5a): 2931-2939
Friedrich, M.; Diesing, D.; Schröer, A. 2004: Hepatic metastasectomy as a cytoreductive strategy for the treatment of liver metastases in breast cancer: review of literature European Journal of Gynaecological Oncology 25(5): 555-558
Fayaz, S.; Demian, G.A.; El-Sherify, M.; Eissa, H.; Aziz, M.; Abuzallouf, S. 2019: Triple Negative Breast Cancer: 10-Year Survival Update of The Applied Treatment Strategy in Kuwait Gulf Journal of Oncology 1(29): 53-59
Chitapanarux, I.; Lorvidhaya, V.; Kamnerdsupaphon, P.; Tharavichitkul, E.; Trakultivakorn, H.; Somwangprasert, A.; Sumitsawan, S.; Srisukho, S.; Watcharachan, K.; Sukthomya, V. 2006: Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(6): 761-766
Liu, L.; Liu, Z-zhe.; Liu, Y-ye.; Zheng, Z-dong.; Liang, X-feng.; Han, Y-ling.; Xie, X-dong. 2013: Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer Zhonghua Zhong Liu Za Zhi 35(12): 936-940
Slee, P.H.T.J.; Rodenburg, C.J.; Nortier, J.W.R.; van Bochove, A. 2004: A phase i dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer Netherlands Journal of Medicine 62(9): 314-319
Halim, A.; Wahba, H. 2012: Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study Journal of BUON: Official Journal of the Balkan Union of Oncology 17(2): 254-258
Hu, Y.-H.; Guo, J.-C.; Zhang, M. 2017: Bipolar androgen therapy: a novel therapeutic strategy for castration-resistant prostate cancer Zhonghua Nan Ke Xue 23(12): 1138-1140
Izumi, M.; Iino, Y.; Yokoe, T.; Inoue, T.; Yamada, T.; Kobayashi, I.; Andoh, T.; Yokota, T.; Iijima, T.; Morishita, Y. 1994: Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(2): 265-268
Pacetti, U.; Veltri, E.; Fattoruso, S.Ileana.Sara.; Cardillo, F.D'Assisi.; Evangelista, S.; Cognetti, F.; Fabi, A. 2013: Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer Anticancer Research 33(4): 1721-1724
Cheng, Y.H.; Jenardhanan, P.; Mathur, P.P.; Qian, X.; Xia, W.; Silvestrini, B.; Cheng, C.Y. 2014: Interaction of oligomeric breast cancer resistant protein (BCRP) with adjudin: a male contraceptive with anti-cancer activity Current Molecular Pharmacology 7(2): 147-153
Walker, A.R.; Walker, B.F. 1993: Breast cancer avoidance--is there really a strategy of hope? South African Medical Journal 83(9): 631-632
Idris, T.; Winter, R.; Lang, U.; Petru, E. 2009: Topotecan-induced long-term remission of an advanced endometrial cancer after treatment with cisplatinum, an anthracycline and paclitaxel Anticancer Research 29(5): 1761-1762
Angelescu, N.; Popa, E.; Bordea, A.; Jitea, N.; Burcoş, T.; Florea, I.; Aldea, C.; Zodieru, I. 2002: The therapeutical strategy for locally advanced breast cancer Chirurgia 97(4): 357-363